A global shortage of ADHD medication is causing concern for New Zealanders who rely on it to manage their condition. ADHD New Zealand spokesman darrin Bull reports that some individuals have resorted to rationing their medication, skipping doses to make their prescriptions last longer.
Teh shortage, which has persisted for over a year, primarily affects methylphenidate, sold under brand names like Ritalin, Concerta, and Teva. This has led to a rise in desperate pleas for help within the ADHD community. “Some of our community [are] asking: ‘can someone please lend me some medication?'” Bull shared, highlighting the severity of the situation.
ADHD affects an estimated 250,000 New Zealanders,but only about 20% receive treatment. While a recent study revealed a tenfold increase in ADHD medication dispensed between 2006 and 2022, the current shortage is causing significant distress. “The ADHD medication is there for a purpose, and without it people can struggle – and really struggle,” Bull emphasized.
Medsafe, new zealand’s medicines regulatory authority, has issued a strong warning against sharing or purchasing prescription medication online or through social media. This practice is illegal and poses serious health risks.
ADHD New Zealand urges those affected to consult their GP or pharmacist for guidance. They also recommend exploring non-medical alternatives such as ADHD coaching, support groups, acupuncture, therapy, and occupational therapy.
A Glimmer of Hope: New Medication Funding
In a positive development, Pharmac, New Zealand’s drug-buying agency, has announced funding for lisdexamfetamine (Vyvanse), an option ADHD medication. Previously available only privately, Vyvanse became publicly subsidized on December 1st, 2023.
Pharmac hopes this move will alleviate pressure on the supply of other ADHD medications. They have mandated that suppliers maintain sufficient stock levels in New Zealand to minimize the risk of future shortages. Though, ADHD New Zealand remains cautious, stating that the immediate impact on the current shortage might potentially be limited due to the requirement for a psychiatrist’s prescription for lisdexamfetamine.
The shortage is expected to continue until mid-2025, underscoring the urgent need for continued support and alternative solutions for individuals with ADHD in New Zealand.
New Zealanders with Attention Deficit Hyperactivity Disorder (ADHD) will soon have access to a groundbreaking medication, funded by the country’s pharmaceutical agency, Pharmac. This move is expected to considerably improve the lives of thousands struggling with the condition.
The medication, which has not been publicly named, is currently only available privately at a considerable cost. “The wait times for an adult assessment for ADHD can be quite long, and you might also find there’s a ample fee if you go private,” said a spokesperson for Pharmac.
Pharmac anticipates that the new medication will benefit over 6,000 individuals with ADHD in it’s first year of funding, with that number projected to rise to 13,000 after five years. This decision marks a significant step forward in ensuring equitable access to essential treatments for ADHD in new Zealand.
For more news and insights from New Zealand, sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday. Click here to subscribe.
## “A Crisis in Focus”: Interview with Darrin Bull on New Zealand’s ADHD Medication Shortage
**World Today News – Auckland, New Zealand**
**[Image: placeholder for image of Darrin Bull]**
The ongoing global shortage of ADHD medication has hit New Zealand hard, leaving many individuals struggling to manage their condition. We spoke with **Darrin Bull**, spokesman for ADHD New Zealand, about the severity of the situation and its impact on the ADHD community.
**World Today News (WTN):** darrin, thanks for speaking with us. Can you tell us more about the nature of the ADHD medication shortage in New Zealand?
**Darrin Bull (DB):** It’s been a arduous year for the ADHD community. For over a year now, we’ve been experiencing a severe shortage of methylphenidate, the primary ingredient in many common ADHD medications like Ritalin, Concerta, and Teva. This shortage has left thousands of Kiwis scrambling to receive the treatment they rely on.
**WTN:** What are some of the consequences you’re seeing as an inevitable result of this shortage?
**DB:** It’s been incredibly distressing. We’re seeing people forced to ration their medication, skip doses, or even go without entirely. This is incredibly damaging, both physically and mentally. ADHD medication isn’t just about focus; it plays a critical role in helping individuals manage daily life. Without it, they can face increased anxiety, depression, and difficulty with work, relationships, and everyday tasks.
**WTN:** You mentioned people resorting to desperate measures. Can you elaborate on that?
**DB:** We’re seeing a surge in pleas for help within the ADHD community. Some reach out, asking if anyone can spare a few pills to get them through until they can access more medication.It’s heartbreaking to see people in such a vulnerable position.
**WTN:** How widespread is this problem, and are there any specific demographics disproportionately affected?
**DB:** ADHD affects an estimated 250,000 New Zealanders, but only about 20% currently receive treatment. While access to diagnosis and treatment has improved in recent years, this shortage threatens to undo that progress. It’s crucial to remember that this isn’t just about “focus pills.” These medications allow individuals with ADHD to fully participate in society and live fulfilling lives.
**WTN:** What is ADHD New Zealand doing to address this crisis?
**DB:** We are advocating tirelessly for immediate action from the government and pharmaceutical companies. This includes pressing for greater transparency around the causes of the shortage and working to secure alternative sources of medication. We’re also providing crucial support to individuals and families struggling to cope with the shortage, connecting them with resources and advocacy networks.
**WTN:** What message would you like to send to the New Zealand government and pharmaceutical companies regarding this issue?
**DB:** This is a public health emergency. We need immediate action to secure a reliable supply of ADHD medication for those who depend on it. We implore you to prioritize the needs of the ADHD community and work collaboratively to find solutions that ensure everyone has access to the treatment they deserve.
**[Image: Placeholder for image of ADHD medication]**
**WTN:** Darrin, thank you for shedding light on this vital issue.
